Skip to Content

Chugai Pharmaceutical Co Ltd ADR CHGCY

Morningstar Rating
$19.22 +0.27 (1.42%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

CHGCY is trading at a 251% premium.
Price
$18.92
Fair Value
$56.22
Uncertainty
High
1-Star Price
$53.00
5-Star Price
$51.85
Economic Moat
Bnrx
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CHGCY is a good fit for your portfolio.

Trading Information

Previous Close Price
$18.95
Day Range
$18.6219.30
52-Week Range
$13.5922.61
Bid/Ask
$19.10 / $19.39
Market Cap
$63.25 Bil
Volume/Avg
43,276 / 85,291

Key Statistics

Price/Earnings (Normalized)
28.79
Price/Sales
8.70
Dividend Yield (Trailing)
1.42%
Dividend Yield (Forward)
1.42%
Total Yield
1.42%

Company Profile

Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan’s oncology market for the past decade, largely due to drugs licensed from its parent’s portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and covid-19 patients.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Core
Total Number of Employees
7,604

Competitors

Valuation

Metric
CHGCY
4502
4568
Price/Earnings (Normalized)
28.7916.2857.83
Price/Book Value
5.750.936.71
Price/Sales
8.701.597.07
Price/Cash Flow
27.107.7843.24
Price/Earnings
CHGCY
4502
4568

Financial Strength

Metric
CHGCY
4502
4568
Quick Ratio
4.210.512.32
Current Ratio
5.531.113.01
Interest Coverage
1.3535.14
Quick Ratio
CHGCY
4502
4568

Profitability

Metric
CHGCY
4502
4568
Return on Assets (Normalized)
17.64%5.19%6.99%
Return on Equity (Normalized)
21.05%11.01%12.93%
Return on Invested Capital (Normalized)
20.98%7.28%10.69%
Return on Assets
CHGCY
4502
4568
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - General Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Eli Lilly and Co
LLY
ZpcljlctcLwrqy$779.7 Bil
Johnson & Johnson
JNJ
MmsgxhhyHlp$371.2 Bil
Merck & Co Inc
MRK
CqfnslycnWggf$318.3 Bil
AbbVie Inc
ABBV
WjtntqlcLsn$306.6 Bil
Roche Holding AG ADR
RHHBY
YyrnymsvwcQhxdr$254.3 Bil
AstraZeneca PLC ADR
AZN
CzlzcmnjtxFwzdy$245.8 Bil
Novartis AG ADR
NVS
DgwhdgvzfZtzdk$219.6 Bil
Amgen Inc
AMGN
CwnglwkmGtlqk$180.2 Bil
Pfizer Inc
PFE
JrmfdbvHvntb$167.7 Bil
Sanofi SA ADR
SNY
YttzcmbySsl$127.5 Bil

Sponsor Center